“A ureteral stent can be bothersome, but it’s quite variable. Some people don’t even feel the stent and some people have severe symptoms,” says Johnathan Harper, MD.
Lead study author Johnathan Harper, MD discusses the background and results of the study, “Risk Factors For Increased Stent-Associated Symptoms Following Ureteroscopy For Urinary Stones: Results From The Urinary Stone Disease Research Network (USDRN) Stents Study,” which he presented at the 2022 AUA Annual Meeting (abstract LBA02-08).
Harper is a professor of Urology and chief of Endourology and Minimally Invasive Surgery at the University of Washington
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.